Sepsis Metabolomics
Systemic Metabolic Changes of Sepsis Patients Revealed by an LC-MS/MS Based Metabolomic Approach
1 other identifier
observational
65
1 country
1
Brief Summary
The occurrence of sepsis and its relevant multiple organ dysfunction remain a major problem in intensive care units with high morbidity and mortality. The differentiation between non-infectious and infectious etiologies, severity and organ function evaluation, and prognostic assessment are all challenging in routine clinical practice. Many biomarkers have been suggested for these purpose; however sensitivity and specificity even of high-ranking biomarkers still remain insufficient. Recently, metabolic profiling has attracted interest for biomarker discovery. In this study, LC-MS/MS will be perform to identify serum metabolic biomarkers for differentiation of SIRS/sepsis, severity and organ function evaluation, and prognostic assessment among 65 patients. The investigators enrolled 35 patients who were diagnosed with sepsis, 15 patients who were diagnosed with SIRS, and 15 normal patients. Moreover, the sepsis were further divided into sepsis, severe sepsis, and sepsis patients before death. Small metabolites that were present in patient serum samples were measured by LC-MS/MS techniques and analyzed using multivariate statistical methods, such as Principal Component Analysis (PCA), Partial Least Squares-Discriminant Analysis (PLS-DA), and Orthogonal Partial Least Squares Discriminant Analysis. Based on the multivariate statistical analysis above, the investigators could distinguish sepsis from normal and SIRS; distinguish the difference among sepsis, severe sepsis and death. We hypothesis that some metabolites as identified in this study are promising biomarker candidates in the field of sepsis diagnosis and treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jul 2010
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2012
CompletedFirst Submitted
Initial submission to the registry
July 23, 2012
CompletedFirst Posted
Study publicly available on registry
July 25, 2012
CompletedJanuary 14, 2014
January 1, 2014
1.7 years
July 23, 2012
January 13, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
death
sepsis patients within 48 hours before death
Study Arms (5)
Normal control
Healthy volunteers
SIRS
1. temperature \>38 ℃ or \<36℃; 2. pulse rate\>90 beats/min; 3. ventilatory rate\>20 breaths/min or hyperventilation with partial pressure of arterial carbon dioxide (PaCO2)\<32mmHg; 4. white blood cell count\>12,000μL-1 or \<4000μL-1 or \>10% immature cells
sepsis
sepsis is defined as SIRS plus confirmed infection.
severe sepsis
1. sepsis associated with organ dysfunction, hypoperfusion, or hypotension. 2. sepsis with arterial hypotension, despite adequate fluid resuscitation.
death
sepsis patients within 48 hours before death.
Eligibility Criteria
All subjects were selected from among inpatients who were hospitalized between July 2010 and Mar 2012 in the Respiratory ICU, Surgical ICU, and Emergency ICU, Chinese People's Liberation Army (CPLA) General Hospital.
You may qualify if:
- male and female aged 18 years old and over;
- clinically confirmed infection;
- fulfilled at least two criteria of systemic inflammatory response syndrome
- core temperature higher than 38 °C or lower than 36 °C
- respiratory rate above 20/min, or PCO2 below 32 mmHg
- pulse rate above 90/min, and
- white blood cell count greater than 12,000/μl or lower than \< 4,000/μl or less than 10% of bands.
You may not qualify if:
- younger than 18 years of age;
- acquired immunodeficiency syndrome;
- reduced polymorphonuclear granulocyte counts (\< 500 μL-1);
- died within 24h after admission into the ICU, or refused to participate in the study, or declined treatment during the period of observation.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China
Related Publications (1)
Su L, Huang Y, Zhu Y, Xia L, Wang R, Xiao K, Wang H, Yan P, Wen B, Cao L, Meng N, Luan H, Liu C, Li X, Xie L. Discrimination of sepsis stage metabolic profiles with an LC/MS-MS-based metabolomics approach. BMJ Open Respir Res. 2014 Dec 10;1(1):e000056. doi: 10.1136/bmjresp-2014-000056. eCollection 2014.
PMID: 25553245DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Lixin Xie, Dr
Department of Respiratory Diseases, Chinese PLA General Hospital
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Dr
Study Record Dates
First Submitted
July 23, 2012
First Posted
July 25, 2012
Study Start
July 1, 2010
Primary Completion
March 1, 2012
Study Completion
March 1, 2012
Last Updated
January 14, 2014
Record last verified: 2014-01